Today's Challenges. Tomorrow's Solutions.

Strategic Solutions for Rheumatology That Protect the Margin in the Drug

In rheumatology, the infused biologic is the business. Fulcrum Health Partners advises independent groups, in-office infusion centers, and PE- and payer-backed platforms on buy-and-bill drug economics — ASP+ under Medicare, AWP/WAC-based commercial terms, biosimilar substitution, and white-bagging defense. We turn a thin, contested drug margin into durable, defensible enterprise value.

Model Your Drug-Margin Opportunity → Speak with a Rheumatology Advisor

$2.7B

Reimbursement Opportunity Identified

12,500+

Payer Contracts Reviewed

States Served

350+

Client Engagements

The Rheumatology Reimbursement Landscape

The clinic bills for care. The economics run on the drug.

In rheumatology, infused biologics dominate the top line — so the practice lives or dies on a buy-and-bill margin that is thin, spread-based, and under active attack.

Infliximab and other IV agents make the medication the largest revenue line by a wide margin, but the money is a spread, not a fee. Medicare pays these Part B drugs at ASP+6% (before sequestration), while commercial plans price off AWP or WAC — so the same vial earns very different margin depending on the payer, the contract, and the acquisition cost you actually paid. E/M visits, infusion administration codes, laboratory panels, and DEXA scans round out the P&L, but none of them approaches the scale of the drug.

At the same time, payers are moving aggressively to pull that drug line out of the office. White- and brown-bagging mandates and specialty-pharmacy carve-outs threaten to strip in-office infusion margin entirely; biosimilar substitution resets the spread on every new ASP cycle; and medical-versus-pharmacy-benefit steerage decides whether the practice touches the drug at all. Layer on step therapy, prior authorization, and the rapid PE consolidation of rheumatology and infusion platforms, and the same infusion suite can be worth dramatically different amounts depending on how it is contracted and defended — which is precisely where Fulcrum works.

Illustrative composition. Replace with your confirmed figures before launch; reflects current CMS Part B ASP methodology and public payer data, 2024–2026.

Net Revenue Composition — Illustrative

Where the rheumatology top line concentrates

Infused biologics (drug)

Infusion administration

E/M visits

Laboratory

DEXA

Net margin retained

The drug dwarfs every other line — but only a thin spread is kept, and payers are working to take it out of the office entirely.

~65%

Of net revenue in the infused-drug line (illustrative)

ASP+6%

Statutory Medicare Part B buy-and-bill add-on, pre-sequestration

Biosimilars

Multiple infliximab & other biosimilars now competing on ASP

Prior authorization & step therapy on nearly every biologic

Reimbursement Intelligence in Action

Your infusion economics, by rheumatology profile

Fulcrum turns your claims, drug-acquisition, and contract data into executive dashboards. Select a profile to explore a sample payer-mix and revenue view — separating the buy-and-bill drug line from the professional and ancillary services around it.

Independent Rheumatology · Payer Mix & Revenue Live Sample

Payer Mix (by active patients)

Net Revenue by Payer — Buy-and-Bill Drug vs. Professional & Ancillary

Buy-and-bill drug (medical-benefit) net revenueE/M, infusion administration, labs & DEXA

Illustrative sample dashboard. Fulcrum builds these from your practice-management, claims, drug-acquisition, and contract data by HCPCS/J-code, payer, and contract.

The Forces Reshaping Rheumatology Economics

The strategic questions every rheumatology leader now faces

Beyond the fee schedule, these are the dynamics that decide whether the infusion suite stays profitable — and where Fulcrum builds the strategy.

Buy-and-Bill Under Pressure

Defending a spread-based margin as ASP+ erodes, sequestration bites, and acquisition costs move independently of what payers allow.

White- & Brown-Bagging Mandates

Countering specialty-pharmacy carve-outs and site-of-care steerage that pull the drug — and its margin — out of the office.

Biosimilar Substitution Economics

Managing the margin reset as infliximab and other biosimilars compete on ASP, WAC, and rebates across every new pricing cycle.

Medical vs. Pharmacy Benefit Steerage

Deciding — and negotiating — whether biologics are adjudicated under the medical or pharmacy benefit, which determines who touches the drug.

Step Therapy & Prior Authorization

Absorbing the administrative tax and delay that gate nearly every biologic start and threaten adherence and revenue timing.

PE & Infusion-Platform Consolidation

Competing with — and evaluating alignment against — the platforms and enablers now rolling up rheumatology and in-office infusion.

Our Rheumatology Advisory Solutions

Advisory organized around the economics you manage

Not a service menu — the reimbursement problems that decide rheumatology margin and enterprise value, and the strategy, analytics, and negotiation capabilities that resolve them.

01 The Challenge — You can't defend a drug margin you haven't benchmarked

Contract Assessment & Reimbursement Benchmarking

We digitize and normalize every payer contract and fee schedule, then benchmark your buy-and-bill drug terms, infusion administration, E/M, and ancillaries against Medicare ASP+ and against market — quantifying exactly where the spread sits and what the opportunity is worth.

Contract digitization

J-code & ASP+ term analysis

AWP/WAC commercial benchmarking

Infusion administration rate review

Biosimilar spread comparison

Acquisition-cost margin mapping

Underpayment identification

Revenue opportunity quantification

Contract performance scoring

02 The Challenge — Payers negotiate the drug away one carve-out at a time

Managed Care Negotiations & Strategy

We build the positioning, data, and negotiation strategy to protect buy-and-bill economics, keep biologics on the medical benefit, and improve infusion and professional terms across every payer — from renewals to executive escalations.

Buy-and-bill term protection

White-bagging & carve-out defense

ASP+ and AWP/WAC rate strategy

Medical- vs. pharmacy-benefit positioning

Biosimilar formulary alignment

Renewals, redlining & escalation

03 The Challenge — Drug-line decisions made without modeling the spread

Contract Modeling & Analytics

J-code- and payer-level modeling that turns claims, contracts, and acquisition cost into scenario analysis, biosimilar switch economics, and side-by-side contract comparisons your executives can act on.

J-code-level margin modeling

Biosimilar switch & ASP scenarios

Site-of-care & carve-out impact

Payer mix & revenue forecasting

ASP+ vs. AWP/WAC comparison

Executive Power BI dashboards

04 The Challenge — Negotiating drug terms blind to competitor pricing

Payer Transparency & Market Rate Intelligence

Federal Transparency in Coverage data has transformed the negotiating table. We mine machine-readable rate files to show what competing groups are actually paid on biologics, administration, and ancillaries — and arm your team with it.

Transparency in Coverage analysis

Drug & administration rate benchmarking

Market rate positioning

Negotiation preparation

Peer comparison

Commercial opportunity sizing

05 The Challenge — Effort spread evenly across unequal payers and drugs

Covered Lives & Market Intelligence

We map covered lives, payer penetration, biologic utilization, and referral dynamics across your market so you prioritize the negotiations, infusion-site decisions, and biosimilar strategies that move the most margin.

Covered-lives analysis

Payer penetration & market share

Biologic utilization & referral patterns

Infusion-site opportunity mapping

Employer & population trends

Commercial opportunity identification

06 The Challenge — Drug and administration terms that aren't honored

Payer / Provider Disputes & Enforcement

When payers reprice biologics, deny administration codes, force white-bagging against contract, or delay high-dollar drug claims, we lead the interpretation, escalation, and enforcement — turning contractual entitlement into collected revenue.

Contract interpretation

Drug-claim & repricing disputes

Site-of-care & carve-out challenges

Escalation support

Executive negotiation

Contract enforcement

07 The Challenge — High-dollar drug dollars that leak both ways

Underpayment / Overpayment Recovery & Revenue Integrity

Our analytics compare contracts, ASP files, allowables, and EOB/remittance data to detect variances on buy-and-bill drugs and administration — quantifying recoverable revenue, flagging overpayment exposure, and fixing the root cause so leakage stops.

Contract compliance auditing

Under- & overpayment detection

ASP & J-code variance analytics

Recovery & appeals strategy

Root-cause remediation

Revenue integrity programs

Rheumatology Drug-Margin Calculator

See what an optimized, defended drug line is worth

Model the annual value of lifting your net buy-and-bill margin — through ASP+ optimization, AWP/WAC-based commercial terms, and biosimilar strategy — plus the margin you defend by keeping drugs off white- and brown-bagging steerage.

Your inputs

Enter approximate figures — nothing is stored or transmitted.

Annual buy-and-bill drug revenue (infused biologics)

Current net drug margin (% of drug revenue)

Optimized net drug margin (% of drug revenue) — 11%

Drug revenue defended from white-/brown-bagging steerage (%)

Estimated annual drug-margin value

Adjust the inputs to model your opportunity.

Per $1M of drug revenue

3-year cumulative

Directional estimate for discussion only. Combines margin optimization on retained drug revenue with margin defended from specialty-pharmacy steerage; E/M, infusion administration, laboratory, and DEXA revenue are additive. A Fulcrum analysis models your actual contracts, ASP files, and acquisition cost.

Client Outcomes

How Fulcrum helps — and what it's worth

Anonymized outcomes from Fulcrum engagements with rheumatology groups and infusion platforms.

Independent Rheumatology

$1.9M

annual drug-margin recovery

Situation: A single-site group was billing biologics well below market and losing spread on biosimilar starts. Result: We renegotiated ASP+ and AWP/WAC terms, aligned the biosimilar mix, and lifted net drug margin without changing a single therapy.

In-Office Infusion Platform

92%

of at-risk drug revenue defended

Situation: A dominant commercial payer moved to mandate white-bagging across the biologic book. Result: We built the clinical and contractual case, escalated to the executive table, and kept the large majority of infusions — and their margin — in-office.

PE-Backed Rheumatology Platform

8 pts

margin from contract harmonization

Situation: A multi-state roll-up carried a patchwork of legacy drug and administration terms. Result: We harmonized contracts, recovered systematic drug underpayments, and lifted EBITDA ahead of a recapitalization.

Why Rheumatology Leaders Choose Fulcrum

The advisor that speaks rheumatology's economic language

Independent by design and fluent in the economics of the infused-drug line — buy-and-bill margin, ASP+ and AWP/WAC terms, biosimilar substitution, white-bagging defense, and in-office infusion-suite economics — delivered by the people who do the work.

Independent Advisor

No networks, no downstream fees — only your economics.

Buy-and-Bill Fluency

Fluent in the drug-spread economics that fund the practice.

Drug & Administration Benchmarking

Market and transparency data behind every ask.

J-Code & ASP Analytics

Modeling down to the drug, the vial, and the spread.

National Payer Experience

Insight into drug policy in every market.

Biosimilar & Site-of-Care Insight

Positioning for substitution and white-bagging pressure.

Negotiation Leadership

Senior advisors at the table, not junior staff.

Data-Driven Support

Dashboards and intelligence that clarify the path.

Fulcrum Intelligence

Rheumatology insights & analysis

Executive briefings on the forces moving rheumatology economics — buy-and-bill margin, biosimilar substitution, white-bagging pressure, and the medical-versus-pharmacy benefit.

The Buy-and-Bill Squeeze: Defending Infusion Margin → Biosimilar Substitution Economics in Rheumatology →

Explore Rheumatology Insights →